It is not clear if, like in RA, citrullination triggers ENO1 autoantibodies in cancer patients, although citrullinated ENO1 was reported to elicit anti-tumor CD4+ T responses in murine tumor xenografts and in ovarian cancer patients (Cook et al., 2018; Brentville et al., 2020). The gene discussed is ENO1; the disease is cancer.